In a significant victory for food transparency advocates, a federal appeals court ruled on January 6, 2026, in favor of Natural Grocers (NASDAQ:NGVC), the Center for Food Safety, and a coalition of plaintiffs.
Abpro Holdings (NASDAQ:ABP) and South Korean biopharma giant Celltrion announced on January 6, 2026, that the U.S. FDA has cleared the Investigational New Drug (IND) application for ABP-102 (CT-P72).
This clearance transitions Abpro’s lead oncology program into the clinic, targeting a wide array of HER2-positive solid tumors, including breast, gastric, colorectal, and pancreatic cancers.
Alumis (NASDAQ:ALMS) surged as much as 82% in early trading Tuesday after its experimental oral drug, envudeucitinib, outperformed both a placebo and Amgen’s blockbuster Otezla in two Phase 3 trials for moderate-to-severe plaque psoriasis.
Genprex (NASDAQ:GNPX) announced landmark preliminary preclinical data on January 6, 2026, for its diabetes gene therapy candidate, GPX-002.
Cognition Therapeutics (NASDAQ:CGTX) announced on January 6, 2026, the publication of peer-reviewed results from its Phase 2 SHIMMER study in the journal Alzheimer's & Dementia.
Amgen (NASDAQ:AMGN) announced on January 6, 2026, the acquisition of Dark Blue Therapeutics, a UK-based biotech, for a total consideration of up to $840 million.
The deal centers on a first-in-class Targeted Protein Degrader (TPD) designed to treat specific, high-risk sub-populations of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).
Actuate Therapeutics (NASDAQ:ACTU) reported successful Phase 1 results from its Actuate-1902 study on January 6, 2026.
The trial evaluated elraglusib, a first-in-class small molecule GSK-3β inhibitor, in 40 pediatric patients (ages 3–21) with relapsed or refractory solid tumors.
Edible Garden AG Incorporated (NASDAQ:EDBL) reported a 26.4% year-over-year increase in preliminary sales for the 2025 holiday period on January 6, 2026.
The gains were driven by robust demand for its core "Controlled Environment Agriculture" (CEA) products and a rapidly expanding retail footprint that now exceeds 5,000 locations across the U.S., Caribbean, and South America.
Atossa Therapeutics (NASDAQ:ATOS) reached a significant regulatory milestone on January 6, 2026, receiving a "Study May Proceed" letter from the U.S. FDA for its Investigational New Drug (IND) application.
Stereotaxis (NYSE:STXS), a global leader in endovascular surgical robotics, announced on Tuesday, January 6, 2026, that it has received U.S. Food and Drug Administration (FDA) approval for its MAGiC™ Magnetic Interventional Ablation Catheter.
TransCode Therapeutics (NASDAQ:RNAZ) today announced positive preclinical data demonstrating that its lead candidate, TTX-MC138, successfully reaches orthotopic glioblastoma tumors following intravenous administration and achieves sustained target engagement against miR-10b.
Lockheed Martin (NYSE:LMT) announced a transformative seven-year framework agreement with the U.S. Department of War on January 6, 2026.
The deal is designed to more than triple the annual production capacity of the PAC-3® Missile Segment Enhancement (MSE) interceptor, surging from current levels of approximately 600 units to a target of 2,000 units per year.
The agreement is a flagship outcome of the Department of War’s new Acquisition Transformation Strategy.
By providing long-term "demand certainty," the framework incentivizes Lockheed Martin and its massive global supply chain to invest in expanded tooling, facilities, and workforce.
To manage the financial burden of such a rapid scale-up, the deal utilizes a "collaborative financing model" that aims for cash neutrality in the early stages, allowing Lockheed to fund the expansion without immediate pressure on its balance sheet.
This "surging" of the "Arsenal of Freedom" follows a record-breaking 2025, where Lockheed Martin delivered 620 PAC-3 MSEs—a 20% year-over-year increase.
The PAC-3 MSE is a "hit-to-kill" interceptor, meaning it uses pure kinetic energy rather than a blast-fragmentation warhead to neutralize threats, making it the premier defense against advanced ballistic missiles, cruise missiles, and emerging hypersonic threats.
